Pune, India

D Ausekar Govind

This inventor holds 1 USPTO granted patent. Top assignee: Lupin, Inc.. Active years: 2020.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: D Ausekar Govind: Innovator in Pharmaceutical Chemistry

Introduction

D Ausekar Govind is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for drug formulation. His work is characterized by a focus on improving the stability and purity of pharmaceutical compounds.

Latest Patents

D Ausekar Govind holds a patent for the "Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3." This invention provides improved, commercially viable, and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and its pharmaceutical composition. This innovation is crucial for enhancing the efficacy and safety of the drug.

Career Highlights

Govind is currently associated with Lupin, Inc., a leading global pharmaceutical company. His role at Lupin has allowed him to leverage his expertise in pharmaceutical processes, contributing to the company's mission of providing high-quality medications to patients worldwide.

Collaborations

Throughout his career, D Ausekar Govind has collaborated with several talented professionals, including G Varade Shantanu and Girij Pal Singh. These collaborations have fostered a productive environment for innovation and have led to advancements in pharmaceutical research.

Conclusion

D Ausekar Govind's contributions to pharmaceutical chemistry, particularly through his patent on Raltegravir potassium, highlight his role as an innovator in the industry. His work continues to impact the field positively, ensuring the availability of effective medications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…